Table 2 Comparison of clinical characteristics between outpatients and care home patients.

From: Evaluation of bone fragility in cognitively or physically impaired elderly care home patients using radiofrequency echographic multi-spectrometry

 

Outpatients (N = 189)

Care home patients (N = 71)

P-value

Sex, Male : Female

17 : 172

22 : 49

 < 0.001*

Mean age, years

80.85 (6.32)

86.13 (6.15)

 < 0.001*

Weight, kg

50.60 (8.74)

48.30 (9.52)

0.065

Height, cm

147.56 (7.99)

151.63 (9.27)

 < 0.001*

Body mass index, kg/m2

23.25 (3.67)

21.14 (4.53)

 < 0.001*

Present illness

   

 RA

8 (4.2%)

1 (1.4%)

0.269

 DM

29 (15.3%)

21 (29.6%)

0.009*

 CKD

23 (12.2%)

3 (4.2%)

0.057

 Malignant tumor

20 (10.6%)

14 (19.7%)

0.052

Medication

   

 GC

11 (5.8%)

1 (1.4%)

0.132

 Daily dose

4.64 (2.91)

4.00

 Sleeping pills

46 (24.3%)

25 (35.2%)

0.080

 Antidepressant

2 (1.1%)

8 (11.3%)

 < 0.001*

 Warfarin

3 (1.6%)

6 (8.5%)

0.007*

 Osteoporosis treatment

158 (83.6%)

9 (12.7%)

 < 0.001*

 BP

43 (27.2%)

6 (66.7%)

 

 DMAb

54 (34.2%)

0 (0%)

 

 PTH

3 (1.9%)

0 (0%)

 

 SERM

21 (13.3%)

0 (0%)

 

 ROMO

8 (5.1%)

0 (0%)

 

 VD alone

3 (1.9%)

3 (33.3%)

 

 Smoking

12 (6.3%)

10 (14.1%)

0.046*

 Drinking

28 (14.8%)

8 (11.3%)

0.463

 History of fragility fractures

77 (40.7%)

40 (56.3%)

0.024*

  1. Data presented as average (standard deviation of the mean) and number of cases (percentage).
  2. RA: rheumatoid arthritis; DM: diabetes mellitus; CKD: chronic kidney disease; GC: glucocorticoids; BP: bisphosphonate; DMAb: denosumab; PTH: parathyroid hormone; SERM: Selective Estrogen Receptor Modulator; ROMO: romosozumab; VD: vitamin D3 preparation.
  3. *P < 0.05: There were significant differences between the groups.